>北美循环肿瘤细胞 (CTC) 液体活检市场，按技术（CTC 检测方法、CTC 富集方法、体外正向选择、基于分子 (RNA) 的技术、功能性体外细胞侵袭试验、异种移植模型、微芯片、单螺旋微通道、负向选择和免疫细胞化学技术）、应用（癌症干细胞研究、多种染色体异常及其他）、最终用户（研究和学术机构、参考实验室和医院和医生实验室）、国家（美国、加拿大、墨西哥）划分 - 行业趋势和预测 -2029 年
市场分析与洞察：北美循环肿瘤细胞 (CTC) 液体活检市场
北美循环肿瘤细胞 (CTC) 液体活检市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场将以 25.9% 的复合年增长率增长，预计到 2029 年将从 2021 年的 4.4264 亿美元达到 26.5096 亿美元。慢性病的高患病率和为其有效应用而不断增加的研发活动可能是预测期内推动市场需求的主要驱动力。
液体活检是一种非侵入性血液检测，可检测原发性肿瘤和转移性肿瘤部位释放到血液中的循环肿瘤细胞和肿瘤 DNA 片段。它是一种简单而精确的手术活检替代方法，可让外科医生在非常早期的阶段发现癌症。
循环肿瘤细胞是一类罕见的细胞亚群，可作为转移的种子。它存在于患有实体瘤的患者的血液中。循环肿瘤细胞检测可以检测和量化癌症患者血液中的肿瘤细胞。循环肿瘤细胞 (CTC) 存在各种类型的生物表型，包括干细胞样或混合型、间充质型或上皮型。这些表型在血液中的数量非常少。因此，它们的检测需要一个分离-富集阶段。之后，进行第二阶段的检测。
由于其功效，循环肿瘤细胞 (CTC) 液体活检的需求不断增长，癌症的高发性是预测期内推动循环肿瘤细胞 (CTC) 液体活检市场需求的主要驱动因素。然而，监管和报销情况不明朗，技术人员短缺，正在抑制预测期内循环肿瘤细胞 (CTC) 液体活检市场的增长。
北美循环肿瘤细胞 (CTC) 液体活检市场报告提供了市场份额、新发展和国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案，以实现您的期望目标。
北美循环肿瘤细胞 (CTC) 液体活检市场范围和市场规模
北美循环肿瘤细胞 (CTC) 液体活检市场根据技术、应用和最终用户分为三个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据技术，循环肿瘤细胞 (CTC) 液体活检市场细分为 CTC 检测方法、CTC 富集方法、体外正向选择、基于分子 (RNA) 的技术、功能性体外细胞侵袭试验、异种移植方法、微芯片、单螺旋微通道、负向选择和免疫细胞化学技术。2021 年，CTC 检测方法领域预计将占据市场主导地位，因为学术界和研究中心越来越多地使用该技术进行液体活检测试。
- 根据应用，循环肿瘤细胞 (CTC) 液体活检市场细分为癌症干细胞研究、多种染色体异常等。2021 年，由于对癌症早期诊断和治疗的需求不断增加，预计癌症干细胞研究领域将占据市场主导地位。
- 根据最终用户，循环肿瘤细胞 (CTC) 液体活检市场细分为研究和学术机构、参考实验室以及医院和医生实验室。2021 年，学术和研究机构部门预计将占据市场主导地位，因为研究和学术机构在加速与液体活检相关的各个治疗领域的研究和开发方面发挥着重要作用。
北美循环肿瘤细胞 (CTC) 液体活检市场国家级分析
对北美循环肿瘤细胞 (CTC) 液体活检市场进行了分析，并按国家、技术、应用和最终用户提供了市场规模信息。
北美循环肿瘤细胞（CTC）液体活检市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于癌症患者数量的增加和主要市场参与者的存在，美国在北美地区的循环肿瘤细胞 (CTC) 液体活检中占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
先进技术的存在和参与者采取的战略举措正在为北美循环肿瘤细胞 (CTC) 液体活检市场创造新的机遇
北美循环肿瘤细胞 (CTC) 液体活检市场还为您提供每个国家/地区特定行业增长的详细市场分析，包括产品销售、市场发展的影响以及监管环境的变化及其对牙科器械市场的支持。数据涵盖 2011 年至 2020 年的历史时期。
竞争格局和北美循环肿瘤细胞 (CTC) 液体活检市场份额分析
北美循环肿瘤细胞 (CTC) 液体活检市场竞争格局提供竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对循环肿瘤细胞 (CTC) 液体活检市场的关注有关。
提供循环肿瘤细胞（CTC）液体活检的主要公司有 Eurofins Genomics（Eurofins Scientific 的子公司）、MDx Health、Guardant Health、IMMUCOR、Thermo Fisher Scientific, Inc.、Menarini Silicon Biosystems、QIAGEN、Exact Sciences Corporation、Myriad Genetics, Inc.、LungLife AI, Inc.、Bio-Rad Laboratories, Inc.、Illumina, Inc.、Natera Inc.、ExoDx（Bio-Techne Corporation 的子公司）、Biocept, Inc.、F. Hoffman-La Roche Ltd.、FOUNDATION MEDICINE, INC.、Lucence Health, Inc.、Inivata Ltd、Biolidics Limited、Vortex Biosciences 等。
例如，
- 2020 年 11 月，Lucence Health, Inc. 宣布启动首项早期检测研究，评估其液体活检技术的使用情况。这将有助于该公司推进新产品的推出。
市场参与者的合作、合资和其他策略正在增强公司在循环肿瘤细胞（CTC）液体活检市场中的市场，这也为该组织改善其在循环肿瘤细胞（CTC）液体活检市场中的产品提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TECHNOLOGY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 REGULATIONS: NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
5.1 ROLE OF FDA
5.2 ROLE OF CDC AND HCFA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 HIGH PREVALENCE OF CANCER
6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY
6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER
6.1.4 RISE IN FDA APPROVAL
6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY
6.2 RESTRAINTS
6.2.1 DOWNSIDES OF LIQUID BIOPSY
6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES
6.4 CHALLENGES
6.4.1 SHORTAGE OF SKILLED PERSONNEL
6.4.2 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
7.5 CONCLUSION:
8 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 CTC DETECTION METHODS
8.3 CTC ENRICHMENT METHODS
8.4 EX VIVO POSITIVE SELECTION
8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES
8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY
8.7 XENOTRANSPLANTATION MODELS
8.8 MICROCHIPS
8.9 SINGLE SPIRAL MICROCHANNEL
8.1 NEGATIVE SELECTION
8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES
9 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER STEM CELL RESEARCH
9.3 MULTIPLE CHROMOSOME ABNORMALITIES
9.4 OTHERS
10 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER
10.1 OVERVIEW
10.2 RESEARCH & ACADEMIC INSTITUTES
10.3 REFERENCE LABORATORIES
10.4 HOSPITALS AND PHYSICIAN LABORATORIES
11 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GUARDANT HEALTH
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 FOUNDATION MEDICINE, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 ILLUMINA, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NATERA, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 BIO-RAD LABORATORIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 QIAGEN
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 THERMO FISHER SCIENTIFIC INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 BIOCEPT, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 BIOLIDICS LIMITED
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EXACT SCIENCES CORPORATION
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION)
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 RECENT FINANCIALS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 IMMUCOR
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INIVATA LTD
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUCENCE HEALTH, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 LUNGLIFE AI, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 MDXHEALTH
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 MENARINI SILICON BIOSYSTEMS
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENTS
14.2 MYRIAD GENETICS, INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 VORTEX BIOSCIENCES
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA CTC DETECTION METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA CTC ENRICHMENT METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA EX VIVO POSITIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA MOLECULAR (RNA)-BASED TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA FUNCTIONAL IN VITRO CELL INVASION ASSAY IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA XENOTRANSPLANTATION MODELS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA MICROCHIPS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA SINGLE SPIRAL MICROCHANNEL IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA NEGATIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA IMMUNOCYTOCHEMICAL TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA CANCER STEM CELL RESEARCH IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA MULTIPLE CHROMOSOME ABNORMALITIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA RESEARCH & ACADEMIC INSTITUTES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA REFERENCE LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA HOSPITALS AND PHYSICIAN LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 U.S. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 25 U.S. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 U.S. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 CANADA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 28 CANADA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 29 CANADA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 MEXICO CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 31 MEXICO CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 MEXICO CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CTC DETECTION METHODS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
FIGURE 15 PREVALENCE OF BREAST CANCER IN EUROPE, INDIA, AND IN THE U.S.
FIGURE 16 PREVALENCE OF LUNG CANCER IN VARIOUS COUNTRIES, WITH HUNGARY BEING THE HIGHEST PREVALENCE RATE IN WOMEN AND MEN
FIGURE 17 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2021
FIGURE 18 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 19 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 20 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 21 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2021
FIGURE 22 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2021
FIGURE 26 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SNAPSHOT (2021)
FIGURE 30 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021)
FIGURE 31 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY (2022-2029)
FIGURE 34 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
